AIM ImmunoTech (LSE:0A4Y) - Stock Price, News & Analysis

0A4Y Stock Overview

0A4Y fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 57.62% per year

Risk Analysis

Makes less than USD$1m in revenue ($202K)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($21M)

+ 1 more risk

AIM ImmunoTech Inc. Competitors

Verici Dx

AIM:VRCI

UK£18.2m

OptiBiotix Health

AIM:OPTI

UK£18.6m

Oncimmune Holdings

AIM:ONC

UK£17.4m

Synairgen

AIM:SNG

UK£11.9m

Price History & Performance

Summary of all time highs, changes and price drops for AIM ImmunoTech
Historical stock prices
Current Share Price	US$0.42
52 Week High	US$0.72
52 Week Low	US$0.38
Beta	-0.15
1 Month Change	-14.41%
3 Month Change	0.072%
1 Year Change	-14.96%
3 Year Change	-79.39%
5 Year Change	n/a
Change since IPO	-98.31%

Recent updates

Shareholder Returns

	0A4Y	GB Biotechs	GB Market
7D	0%	3.8%	2.0%
1Y	-15.0%	-23.3%	4.5%

Return vs Industry: 0A4Y exceeded the UK Biotechs industry which returned -26.7% over the past year.

Return vs Market: 0A4Y underperformed the UK Market which returned 3% over the past year.

Price Volatility

Is 0A4Y's price volatile compared to industry and market?
0A4Y volatility
0A4Y Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.3%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.4%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0A4Y's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 0A4Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1966	27	Thomas Equels	aimimmuno.com

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.

AIM ImmunoTech Inc. Fundamentals Summary

How do AIM ImmunoTech's earnings and revenue compare to its market cap?
0A4Y fundamental statistics
Market cap	US$20.96m
Earnings (TTM)	-US$28.96m
Revenue (TTM)	US$202.00k

103.8x

P/S Ratio

-0.7x

P/E Ratio

Is 0A4Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A4Y income statement (TTM)
Revenue	US$202.00k
Cost of Revenue	US$42.00k
Gross Profit	US$160.00k
Other Expenses	US$29.12m
Earnings	-US$28.96m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.58
Gross Margin	79.21%
Net Profit Margin	-14,337.62%
Debt/Equity Ratio	0%

How did 0A4Y perform over the long term?

See historical performance and comparison

0A4Y Stock Overview

Rewards

Risk Analysis

AIM ImmunoTech Inc. Competitors

AIM:VRCI

UK£18.2m

AIM:OPTI

UK£18.6m

AIM:ONC

UK£17.4m

AIM:SNG

UK£11.9m

Price History & Performance

Recent News & Updates

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$0.60 loss per share (vs US$0.41 loss in FY 2022)

AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024

AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding

Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

Recent updates

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$0.60 loss per share (vs US$0.41 loss in FY 2022)

AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024

AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding

Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.13 loss in 3Q 2022)

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen

AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation

Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.10 loss in 2Q 2022)

AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi (Durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.08 loss in 1Q 2022)

Insufficient new directors

Insufficient new directors

AIM ImmunoTech Inc. Announces the Netherlands Patent Office (Octrooicentrum Nederland) Grants A Utility Patent Covering Rugged dsRNA, A Double-Stranded RNA Product Related to Ampligen® (Rintatolimod)

Executive Vice Chairman recently bought US$50k worth of stock

Insufficient new directors

AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer

Aim Immunotech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Insufficient new directors

AIM ImmunoTech Inc. Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen

ASFV Committee Issues a Statement on Ruling in Delaware Action

ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action

Jonathan Thomas Jorgl Issues an Investor Presentation to Shareholders of AIM ImmunoTech

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech

AIM Immunotech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-Covid Conditions

Jonathan Thomas Jorgl Mails a Letter to Shareholders of AIM ImmunoTech

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc. and Study Collaborator Roswell Park Commence Enrollment in an NCI-Funded Phase 2 Clinical Trial Evaluating Ampligen® (Rintatolimod) in Primary Pd-1/Pd-L1 Resistant Melanoma

AIM ImmunoTech Inc. Announces Commencement of Phase 2 Study of Ampligen(R) for the Treatment of Pancreatic Cancer

Jonathan Jorgl Reiterates Intent to Proceed with Nominations and Proxy Solicitation

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen as Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-Free and Overall Survival over Previously Published Data

Insufficient new directors

AIM ImmunoTech Inc. Provides Update on Ampligen Long COVID Development Program

AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies

AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Announces Positive Data from Phase 1 Study Evaluating Ampligen

Full year 2021 earnings released: US$0.40 loss per share (vs US$0.45 loss in FY 2020)

Insufficient new directors

AIM ImmunoTech Inc. Announces Executive Changes

AIM ImmunoTech Inc. Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer

Third quarter 2021 earnings released: US$0.08 loss per share (vs US$0.085 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19

AIM Immunotech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-Covid-19 Cognitive Dysfunction

AIM ImmunoTech Inc. Provides Status Update on its Pending Phase 2A Human Challenge Trial Using its Drug Ampligen